Profile data is unavailable for this security.
About the company
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
- Revenue in CHF (TTM)6.03m
- Net income in CHF-98.18m
- Incorporated2017
- Employees49.00
- LocationRelief Therapeutics Holding SAAvenue de Secheron 15GENEVE 1202SwitzerlandCHE
- Phone+41 447235959
- Fax+41 447269012
- Websitehttps://relieftherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prolight Diagnostics AB (publ) | 0.00 | -11.18m | 13.96m | 16.00 | -- | 1.15 | -- | -- | -0.3953 | -0.3953 | 0.00 | 0.2488 | 0.00 | -- | -- | 0.00 | -64.42 | -- | -84.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| Active Biotech AB publ | 0.00 | -3.66m | 14.55m | 8.00 | -- | 8.85 | -- | -- | -0.1651 | -0.1651 | 0.00 | 0.0556 | 0.00 | -- | -- | -- | -122.57 | -57.97 | -179.56 | -97.83 | -- | -- | -- | -1,454.61 | -- | -- | 0.1145 | -- | -- | -- | 21.54 | -- | -- | -- |
| Read Gene SA | 2.41m | -324.29k | 14.82m | 11.00 | -- | 15.00 | -- | 6.14 | -0.1551 | -0.1551 | 1.07 | 0.3732 | 0.7606 | 9.91 | 9.55 | -- | -10.22 | -1.06 | -10.58 | -1.31 | 91.56 | 88.41 | -13.44 | -2.42 | 10.10 | -3.45 | 0.00 | -- | 40.14 | 16.00 | -731.53 | -- | -- | -- |
| LungLife AI Inc | 40.67k | -4.78m | 15.15m | 15.00 | -- | 0.5588 | -- | 372.58 | -0.165 | -0.165 | 0.0014 | 0.2412 | 0.0038 | -- | 0.2831 | 2,382.43 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Nanogroup SA | -5.61k | -1.65m | 16.42m | -- | -- | 22.94 | -- | -- | -0.3477 | -0.3477 | -0.0012 | 0.1587 | -0.0016 | 7.38 | -- | -- | -47.32 | -23.18 | -59.79 | -26.06 | -- | -278.03 | -- | -1,567.57 | 0.4541 | -2,241.44 | 0.00 | -- | -98.55 | -55.07 | -840.84 | -- | -8.99 | -- |
| RELIEF THERAPEUTICS Holding SA | 6.03m | -98.18m | 16.85m | 49.00 | -- | 0.2881 | -- | 2.79 | -8.45 | -8.45 | 0.5133 | 4.16 | 0.0455 | 4.43 | 3.25 | 123,122.40 | -74.05 | -33.48 | -79.32 | -36.18 | 71.22 | -- | -1,627.40 | -1,289.04 | 2.57 | -- | 0.0763 | -- | -0.7893 | 60.58 | -93.31 | -- | -- | -- |
| SenzaGen AB | -8.17bn | -8.17bn | 16.88m | 32.00 | -- | 2.58 | -- | -- | -- | -- | -- | 2.71 | -- | -- | -- | -- | -- | -25.84 | -- | -29.85 | -- | 68.62 | -- | -132.29 | 1.24 | -- | 0.0368 | -- | 19.39 | 90.32 | 11.30 | -- | -21.10 | -- |
| Plant Advanced Technologies PAT SA | 1.61m | 75.97k | 16.90m | 27.00 | 219.46 | 2.06 | 30.38 | 10.47 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | 62,278.52 | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Kancera AB | 0.00 | -4.93m | 17.06m | 5.00 | -- | 2.22 | -- | -- | -0.7267 | -0.7267 | 0.00 | 0.7749 | 0.00 | -- | -- | 0.00 | -52.92 | -54.82 | -65.84 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
| Alzinova AB | 24.52k | -1.40m | 17.17m | 5.00 | -- | 1.28 | -- | 700.20 | -0.3221 | -0.3221 | 0.0056 | 1.98 | 0.0027 | -- | 0.4459 | 60,000.00 | -15.32 | -10.77 | -16.22 | -11.27 | 6,018.45 | -- | -5,723.82 | -18,447.90 | -- | -- | 0.0073 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
| Biovica International AB | 596.02k | -10.20m | 17.90m | 32.00 | -- | 2.45 | -- | 30.03 | -2.12 | -2.12 | 0.1218 | 1.15 | 0.048 | 0.2322 | 6.50 | 227,843.80 | -82.20 | -51.94 | -99.16 | -58.18 | 94.34 | 181.68 | -1,712.00 | -2,217.41 | 3.04 | -- | 0.0749 | -- | 115.49 | 19.39 | -12.97 | -- | -54.31 | -- |
| Shield Therapeutics PLC | 14.89m | -37.88m | 18.24m | 73.00 | -- | 1.07 | -- | 1.23 | -0.0458 | -0.0458 | 0.0181 | 0.0192 | 0.347 | 3.65 | 1.31 | 179,246.60 | -88.29 | -56.68 | -136.30 | -67.44 | 30.78 | 52.20 | -254.44 | -365.89 | 2.04 | -30.01 | 0.5739 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
| Phaxiam Therapeutics SA | 1.27m | -22.54m | 18.39m | 51.00 | -- | 0.4927 | -- | 14.45 | -5.14 | -5.14 | 0.2901 | 3.90 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Exact Therapeutics AS | 0.00 | -3.88m | 18.39m | 8.00 | -- | 5.09 | -- | -- | -1.51 | -1.51 | 0.00 | 1.41 | 0.00 | -- | -- | -- | -67.21 | -40.21 | -86.14 | -45.67 | -- | -- | -- | -- | -- | -16,578.57 | 0.0258 | -- | -- | -- | -20.52 | -- | -- | -- |
| Thor Medical ASA | 0.00 | -445.89k | 19.32m | 1.00 | -- | 0.8812 | -- | -- | -0.0318 | -0.152 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -2.52 | -79.17 | -2.84 | -113.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
Data as of Jul 26 2024. Currency figures normalised to Relief Therapeutics Holding SA's reporting currency: Swiss Franc CHF
10.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 27 Jun 2023 | 1.20m | 8.55% |
| Credit Suisse Asset Management (Schweiz) AGas of 28 Jun 2024 | 83.16k | 0.59% |
| Herculis Partners SAas of 31 Jan 2020 | 82.50k | 0.59% |
| Z�rcher Kantonalbank (Investment Management)as of 31 May 2024 | 49.25k | 0.35% |
| UBS Asset Management Switzerland AGas of 02 Jul 2024 | 48.88k | 0.35% |
| Pictet Asset Management SAas of 31 Mar 2024 | 19.43k | 0.14% |
| Credit Suisse AGas of 31 May 2024 | 8.81k | 0.06% |
| BlackRock Asset Management Schweiz AGas of 04 Jul 2024 | 5.22k | 0.04% |
| Lombard Odier Asset Management (Switzerland) SAas of 31 May 2024 | 3.49k | 0.03% |
| DWS CH AGas of 31 May 2024 | 2.54k | 0.02% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
